Risk management materials for Ilaris (canakinumab) 150mg powder for solution for injection -

Risk management materials for Ilaris (canakinumab) 150mg powder for solution for injection
Information type: Safety alerts
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Haematological disorders | Musculo-skeletal disorders
Summary
A guide for injection preparation and administration for healthcare professionals when using Ilaris for gouty arthritis has been published. A separate guide for patients who have been prescribed Ilaris for Cryopyrin-Associated Periodic Syndromes (CAPS) has also been issued.
UKMi comment
Important safety information for consideration with the prescribing of canakinumab for gouty arthritis, CAPS, and Still's Disease (including Adult-Onset Still's Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [SJIA]) has also been issued for healthcare professionals.

Additionally, safety information for patients with these conditions have been issued in the form of Patient Alert Cards.
Related links: Injection preparation and administration guide for patients with CAPS Injection preparation and administration guide for patients with Still's Disease (Adult-Onset Still's Disease and Systemic Juvenile Idiopathic Arthritis Healthcare Professional’s Guide to Treatment of Patients with CAPS Healthcare Professional’s Guide to Treatment of Patients with gouty arthritis Healthcare Professional’s Guide to Treatment of Patients with Still's Disease (Adult-Onset Still's Disease and Systemic Juvenile Idiopathic Arthritis)Patient Alert Card for patients with CAPS Patient Alert Card for patients with gouty arthritis Patient Alert Card for patients with Still's Disease (Adult-Onset Still's Disease and Systemic Juvenile Idiopathic Arthritis)